Onconetix (ONCO) investor relations material

Company overview and business model

• Commercial-stage biotechnology company focused on oncology diagnostics, primarily commercializing Proclarix, a protein-based blood test for prostate cancer, with CE-marking in Europe and ongoing U.S. validation studies in partnership with Labcorp.

• Abandoned commercialization of ENTADFI due to resource constraints and fully impaired related assets as of June 2024.

• Relies on third-party manufacturing and distribution, with no internal manufacturing capabilities.

• Ongoing efforts to expand Proclarix sales in Europe and the U.S., with anticipated revenue growth but continued reliance on external capital.

Financial performance and metrics

• Net loss of $14.0 million for 2025 and $58.7 million for 2024; accumulated deficit of $135.4 million as of March 31, 2026.

• Cash balance of $3.7 million as of March 31, 2026, and $6.5 million as of June 5, 2026; working capital of $1.3 million.

• Generated $11.3 million in proceeds from 2.6 million shares sold under the ELOC Purchase Agreement through June 5, 2026.

• Management believes current cash is insufficient to fund operations for one year, raising substantial doubt about going concern status.

Use of proceeds and capital allocation

• May receive up to $25 million in gross proceeds from Keystone under the ELOC Purchase Agreement, with 30% of proceeds allocated to redeem Series C Preferred Stock.

• Remaining proceeds to be used for general corporate purposes and working capital as determined by the Board.